Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | PDE2A | O00408 | 3/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.38 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.38 |
| ▸ | CD99 | P14209 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12223717 | 1.00 | NT5E (0.43) | NT5ELMNAHIF1ACA5AADORA2A | |
| SCHEMBL30141033 | 0.84 | TYMP (0.42) | NT5EADORA1PDE2A | |
| SCHEMBL26355063 | 0.83 | DOT1L (0.35) | NT5EADORA2AADORA2B | |
| SCHEMBL31359555 | 0.77 | TYMP (0.42) | NT5ELMNAHIF1ACA5AADORA2A | |
| SCHEMBL26554236 | 0.75 | PRMT6 (0.43) | LMNAADORA1 | |
| SCHEMBL18510956 | 0.75 | PRMT6 (0.43) | LMNAADORA1 | |
| SCHEMBL20248724 | 0.75 | PRMT6 (0.43) | LMNAADORA1 | |
| SCHEMBL30140974 | 0.75 | TYMP (0.40) | NT5ELMNAHIF1ACA5AADORA2A | |
| SCHEMBL30140968 | 0.75 | TYMP (0.40) | NT5ELMNAHIF1ACA5AADORA2A | |
| SCHEMBL6753322 | 0.74 | HINT1 (0.42) | NT5EADORA2AADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118339-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110065774-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | ALNYLAM PHARMACEUTICALS (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065774-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | DCLRE1B, RNGTT, NSUN2 | NT5E 32/4885LMNA 3915/4885HIF1A 2130/4885 |
| US-20110118339-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | TRDMT1, NSUN3, BCDIN3D | NT5E 38/4885LMNA 487/4885HIF1A 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.